Kymera Therapeutics

Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline WATERTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule